A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

• Main Authors: Curtis K. Johnston (Author), Rena J. Eudy-Byrne (Author), Ahmed Elmokadem (Author), Valerie Nock (Author), Jan Marquard (Author), Nima Soleymanlou (Author), Matthew M. Riggs (Author), Karl-Heinz Liesenfeld (Author)
• Format: Book
• Published: MDPI AG, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

In clinical trials, sodium-glucose co-transporter (SGLT) inhibitor use as adjunct to insulin therapy in type 1 diabetes (T1D) provides glucometabolic benefits while diabetic ketoacidosis risk is increased. The SGLT2 inhibitor empagliflozin was evaluated in two phase III trials: EASE-2 and EASE-3. A...